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Caspase function
Apoptosis allows for the removal of defective, redundant, infected, transformed or senescent cells from a population. The genetically controlled pathways that regulate apoptosis are prone to dysfunction; therefore, defects in these pathways contribute to diverse pathological conditions including cancer, diabetes, AIDS, ischemia-reperfusion injury and neurodegenerative disorders. The contribution of apoptosis to pathology of disease is often based on molecular data from patients or mice with defects in known regulators of apoptosis. Among these key regulators of apoptosis is the caspase family of proteases that mediates the proteolytic disassembly of the dying cell via cleavage of specific substrates
. [2] . Caspases therefore have diverse roles in protecting the body from disease [3] .
Caspases are normally present in cells as inactive precursors that are activated at the onset of and during the progression of apoptosis. However, their functions are not restricted to cell death regulation. For example, caspase-1 cleaves the pro-inflammatory cytokines, pro-intereukin-1␤ and pro-interleukin-18 to their mature forms and has fundamental roles on variety of aspects of innate immune function
The caspases can be divided into two groups: initiator caspases, including caspase-1, -8, -9 and -10, and executioner caspases, such as caspase-3 and -7 [4] . Executioner caspases are responsible for the cleavage of numerous structural and regulatory proteins, required to dismantle the cell [1] . Initiator caspases are so-called because they are the first to be activated in a pathway. For example, many genotoxic stresses trigger the activation of caspase-9 by engaging the mitochondrial pathway, inducing mitochondrial outer membrane permeabilization (MOMP) and cytochrome c release [5] . in contrast, is activated by death receptors, such as Fas and TNFR1 [6] . These initiator caspases function primarily to cleave and activate executioner caspases, but they can cleave additional proteins to promote apoptosis. For example, in some cell types caspase-8 cleaves the BH3-only protein Bid to promote MOMP [7] .
Initiator caspases are activated by induced proximity of inactive monomers to form an active dimer [8, 9] , which is facilitated by the recruitment of initiator caspases to large molecular weight protein complexes that can be considered 'activation platforms'.
Examples of known activation platforms are the death-inducing signalling complex (DISC) for caspase-8 and the Apaf-1 apoptosome for caspase-9 [10].
Caspase-2: initiator or executioner caspase?
Although caspase-2 is the most evolutionarily conserved of all the caspases [11] [14, 15] . Homotypic interactions between adaptor proteins and caspases containing CARDs and death effector domains govern the recruitment of initiator caspases to their activation platforms to result in caspase activation. Caspase-2 contains a CARD in its prodomain suggesting that it is activated similar to initiator caspases [15] .
In cell lysates caspase-2 is spontaneously recruited to a large molecular weight protein complex in a CARD-dependent manner suggesting that caspase-2 is activated by dimerization [16] . Upon dimerization, the caspase-2 precursor promotes its own cleavage to generate the fully processed enzyme (Fig. 1) [21, 22] . Bid, in turn induces release of cytochrome c from mitochondria and subsequent apoptosis (Fig. 2) 
Functions of caspase-2
Role in development
The requirement of caspase-2 in regulating cellular processes and its contribution to pathology of disease has been difficult to determine, primarily because caspase-2 deficient mice survive normally and do not exhibit any prominent developmental defects [28] . This is in contrast to the lethal phenotypes associated with deficiencies in caspase-8 and -9 [29] .
The only developmental abnormality associated with caspase-2 deficiency is that the female mice have excess oocytes [28] . These mice retain a strong neomycin resistance cassette in their genome that may produce defects in expression of neighbouring genes and therefore account for or enhance the observed phenotype. It has not been published if caspase-2 deficient mice that have been independently generated also possess excess oocytes [26] . Nevertheless, a role for caspase-2 in oocyte development is supported by an observation that oocytes from caspase-2 deficient mice were resistant to DNA damage-induced apoptosis [28] and studies in Xenopus oocyte extracts [30] . Oocytes 
Caspase-2 substrates
As discussed, caspase-2 appears to induce apoptosis by cleaving Bid. A number of other proteins have been identified as targets of caspase-2 but in many cases their impact on caspase-2-mediated apoptosis or on additional functions of caspase-2 (e.g. cell cycle arrest) is unclear.
Golgin-160 is a Golgi membrane protein that has been described as a substrate for caspase-2. Cleavage of golgin-160 contributes to the fragmentation of the Golgi apparatus during apoptosis. Golgin-160 is also cleaved by caspase-3 and -7; however, caspase-2 has been detected at the Golgi apparatus and therefore may have more access to golgin-160 than other caspases [34] . [35] . This suggests that golgin-160 cleavage may induce apoptosis directly rather than merely contributing to the execution phase of apoptosis by mediating organelle destruction.
The role of golgin-160 in normal (non-apoptotic) conditions is unclear but expression of a version of this protein that is resistant to caspase cleavage has been shown to protect cells from stress-induced apoptosis
A recent study suggests that RIP1 is a proteolytic target of caspase-2 and that cleavage of RIP1 by caspase-2 contributes to its tumour suppressive function [36] . RIP1 functions to induce NFB activation in response to tumour necrosis factor (TNF)-␣ and DNA damage [37, 38] . Among the many NFB target genes is survivin, which is a member of the IAP protein family. Survivin is an essential mitotic gene that is indispensible for several steps in cell division and is expressed at high levels in the majority of human tumours [39] . Thus caspase-2-mediated cleavage of RIP1 has been proposed to inhibit NFB activation resulting in silencing of survivin gene expression and suppression of tumour growth [36] .
A number of additional proteins have been proposed to be substrates for caspase-2 including ICAD, PARP, BAD, the transcription factor CUX1 and protein kinase C␦ [40] [41] [42] [43] [44] (for a full list see [45] 
Measuring caspase-2 activation during apoptosis
There is a large literature describing stimuli that potentially activate caspase-2 during apoptosis but the ability of these to actually engage caspase-2 is in many cases still debated [46, 47] . A number of these agents are described in Table 1 [27] or pre-MOMP [48, 106] Jurkat [27, 106] , IMR90E1A [48] , Hela [23] Cleavage [27, 106] , siRNA [48] , VDVAD*, VDVADase † [106] , BiFC [23] Cisplatin Pre-MOMP [107, 108] LLC-PK1 [107] , Caov4 (express p53) [108] VDVAD [107] , VDVADase, cleavage [108] , siRNA [107, 108] 
␥-irradiation
Bcl2 insensitive death in absence of CHK1 [91] , Post-MOMP [26] HEK293 [33] , zebrafish embryos with silenced CHK1 [91] , thymocytes [26] bVAD pulldown [33] , cleavage [26, 33] [121] Pre-MOMP (blocked by Bcl2) [121] U937 [120] , CEM [121] Cleavage [121] , siRNA [120] Helicobacter [76] antisense [51] TNF Independent? (cleaved by caspase-3) [127] Human fibroblasts [127] , Hela [23] Cleavage [127] , BiFC [23] Miscellaneous Heat shock Pre-MOMP mouse splenocytes, Jurkat [24] , Hela [23] bVAD pulldown [24] , BiFC [23] Brucella 
Caspase-2 activation platforms
Caspase-2, like other initiator caspases is activated by dimerization upon recruitment to its activation platform [19] . [70] . This results in induced proximity of caspase-2 molecules facilitating dimerization (Fig. 2) . The crystal structure of the PIDD DD and RAIDD DD core complex of the PIDDosome suggests that five DDs of PIDD bind seven DDs of RAIDD [71] . This structure predicts that seven caspase-2 molecules are recruited to the PIDDosome in total.
The activation platform for caspase-2 appears to be a complex of proteins termed the PIDDosome. The PIDDosome consists of the proteins PIDD, RAIDD and caspase-2. When activated, PIDD binds and induces oligomerization of the adaptor protein RAIDD [69]. The binding is mediated through a protein-protein interaction motif present in both proteins known as a death domain (DD). RAIDD, in turn, binds to caspase-2 via a heterotypic CARD:CARD interaction
A second caspase-2 activation platform has been identified to contain PIDD, caspase-2 and the nuclear serine/threonine kinase DNA-PKcs and does not require RAIDD. This so-called nuclear PIDDosome seems to function primarily in the maintenance of a cell cycle checkpoint rather than apoptosis [33] . The existence of a nuclear PIDDosome is consistent with numerous reports that have shown caspase-2 localized to the nucleus and suggest that it functions from the nucleus [72] [73] [74] . The caspase-2 sequence contains a classical nuclear localization sequence and mutation of this region prevents caspase-2 entry into the nucleus [72] . Surprisingly, using caspase-2 BiFC we found was that active caspase-2 was located in the cytoplasm in response to etoposide and other stimuli regardless of the presence or absence of the nuclear localization sequence, suggesting that caspase-2 is not activated in the nucleus [23] Other reports suggest that caspase-2 is recruited to promyelocytic leukaemia protein nuclear bodies (PML-NBs) in the nucleus [79, 80] . PML-NBs are nuclear macromolecular complexes that potentially regulate multiple cellular processes including apoptosis [81] . PML-NBs act as scaffolds for numerous proteins and immunofluorescence studies show co-localization of GFP tagged caspase-2 with PML-NBs suggesting a potential activation platform for caspase-2 [80] . Furthermore, a protein called SP100 appears to reside at these nuclear structures and contains a putative CARD domain [79] . However, a potential interaction between caspase-2 and SP100 has not been confirmed experimentally.
Therefore it is unknown what physiological role, if any, PML-NBs have in the activation of caspase-2.
Regulation of caspase-2 activation
The difficulty in assessing caspase-2 activation may indicate that this caspase is subject to tight regulatory control. Indeed, in the absence of cellular stressors, caspase-2 activation appears to be suppressed by a number of mechanisms.
Inhibition of caspase-2 by Hsp90␣
Heat stress induces apoptosis, but also activates the protective factor HSF-1 [82] . HSF-1 is a transcription factor that induces the expression of a number of heat shock proteins (Hsps) including Hsp90␣ [83] . We observed that HSF-1 potently inhibits caspase-2 activation in response to heat shock and this is mainly due to the activity of the chaperone Hsp90␣ [23] . [87] .
The second site of phosphorylation of caspase-2 is in the linker domain between the large and small subunit (S340 in human beings) [88] [89] . [90] . Caspase-2 splicing appears to be regulated by a candidate tumour suppressor RBM5, which binds caspase-2 pre-mRNA and promotes formation of the caspase-2L species [91] . Therefore the differential expression patterns of the two isoforms of caspase-2 may be associated with levels of expression of RBM5 in various tissues. [32] . Furthermore, activation of caspase-2 has been reported to delay G2 to M progression suggesting a cell cycle checkpoint function for caspase-2 [32, 33] . This appears to correlate with a third phosphorylation event induced by DNA-PKcs at S122 [33] . In contrast to the other phosphorylation events, this phosphorylation activates caspase-2 rather than suppressing it.
Alternatively spliced isoforms of caspase-2
Regulation of caspase-2 during cell-cycle
Caspase-2 in disease Cancer
A role for caspase-2 as a tumour suppressor suggests that caspase-2 may be absent or defective in certain cancers. Caspase-2 is located on human chromosome 7 and maps to the q34-35 segment [93] . The 7q region is frequently deleted or affected in haematological neoplasms [94] . Studies analyzing caspase-2 levels in cancer have so far shown conflicting results. Decreased levels of caspase-2 correlated with drug-resistance in childhood forms of acute lymphoblastic leukaemia (ALL) [95] and decreased caspase-2 and RAIDD expression was observed in mantle cell lymphoma tumour samples [96] . In contrast, increased levels of caspase-2 in acute myelogenous leukaemia and adult ALL have been associated with lower patient survival [97, 98] . Many of these studies were carried out on small sample sizes, which may contribute to the contradictory results. In light on the recent observations that caspase-2 is a potential tumour suppressor, it seems timely to expand on these early investigations.
Neurodegenerative disorders
Caspase-2 has also been implicated in pathologies associated with aging. Caspase-2 activation has been observed in response to a number of forms of neuronal stress including ␤-amyloid, which is the main constituent of amyloid plaques in Alzheimer's disease [53, 59, 60] . Furthermore, increased caspase-2 has been observed in the brains of Alzheimer's disease patients [99] [101] .
Ischemia-reperfusion injury
In a chick cardiomyocyte model of ischemia-reperfusion inhibition of caspase-2 using an inhibitor dramatically decreased cell death [102] . In this type of injury the majority of cellular damage is a result of oxidative stress and a number of conditions that promote oxidative stress have been suggested to activate caspase-2 (Table 1) . Caspase-2 binds a CARD-containing protein called ARC that is expressed almost exclusively in heart and skeletal muscle [103] . ARC was shown to protect cardiomyocytes from oxidative stress induced apoptosis and may do so through inhibition of caspase-2 [104] . Although indirect, these studies may suggest that targeting caspase-2 could protect cells from oxidative stress resulting from ischemia-reperfusion-associated injury. Of course, much more research is required to determine a direct role for caspase-2 in these pathways.
Concluding remarks
Caspase-2 has in some reviews been termed 'the Cinderella caspase' [105] 
